Ads
related to: next gen sequencing companies prices- Metatranscriptomics Seq
Universal rRNA depletion.
Extreme flexibility.
- 16S/ITS Amplicon Seq
Industry-leading turnaround time.
Unparalleled data resolution.
- Full-Length 16S Seq
Unrivaled species resolution.
Unbiased sample preparation.
- Long-Read Metagenome Seq
Assembling complete genomes
from metagenomes
- Metatranscriptomics Seq
Search results
Results From The WOW.Com Content Network
This design is very different from that of Sanger sequencing—also known as capillary sequencing or first-generation sequencing—which is based on electrophoretic separation of chain-termination products produced in individual sequencing reactions. [6] This methodology allows sequencing to be completed on a larger scale. [7]
New England Biolabs (NEB) is an American life sciences company which produces and supplies recombinant and native enzyme reagents for life science research. [2] It also provides products and services supporting genome editing, synthetic biology and next-generation sequencing. [3]
Clear Labs Raised a $60M Series C round led by Morgan Stanley and T. Rowe Price in May 2021. [19] Clear Labs has also received governmental and professional certification for its food safety next generation sequencing platform, including from the International AOAC [20] in December 2019 and the National Poultry Improvement Plan in October 2021 ...
The SRA was started by NCBI in 2007 to collect sequence data produced by next-generation sequencing instruments. [17] DNAnexus developed a new web interface for the SRA and worked with Google to host more than 350 terabytes of DNA sequence data. [ 18 ]
In 2016, Sophia Genetics entered into a comarketing agreement with Illumina allowing the two companies to promote adoption of next- generation DNA sequencing. [18]In 2019, Sophia Genetics formed partnerships with Integrated DNA Technologies and Paragon Genomics, next-generation sequencing (NGS) assay development company, to provide COVID-19 test kits [19] [20]
In July 2015, Natera conducted an initial public offering of common stock at a price of $18.00 per share. The shares trade on the Nasdaq Global Select Market under the symbol "NTRA." [3] In 2017, Natera launched the Vistara single-gene NIPT. That same year, Natera introduced the Signatera molecular residual disease (MRD) test for research use only.
Ads
related to: next gen sequencing companies prices